Vaccine, MMR


Concise Prescribing Info
Indications/Uses
Active immunisation against measles, mumps, and rubella.
Dosage/Direction for Use
Adult : IM/SC Primary immunisation: 1 or 2 doses of 0.5 mL given at least 28 days apart or based on national recommendation. For post-exposure prophylaxis against measles: Administer within 72 hours of contact. For outbreaks: Refer to detailed product guideline or national protocol.
Dosage Details
Parenteral
Active immunisation against measles, mumps and rubella
Adult: Primary immunisation: 1 dose of 0.5 mL given via IM or deep SC inj, a 2nd dose may be given at an interval of at least 28 days or based on national recommendation. For post-exposure prophylaxis against measles: Administer within 72 hours of contact. For outbreaks: Refer to detailed product guideline or national protocols.
Child: Primary immunisation: ≥12 months 1 dose of 0.5 mL at 12-15 months; repeated at 4-6 years of age (preferably prior to elementary school entry). For outbreaks: Refer to detailed product guideline or national protocols.
Reconstitution
Reconstitute with the provided diluent using aseptic technique. Gently agitate to mix thoroughly.
Incompatibility
Do not mix with other vaccines. Use separate needles and syringes for each inj.
Contraindications
Hypersensitivity. Patient with current febrile respiratory illness or infections, blood dyscrasias, leukaemia, lymphomas, history of congenital or hereditary immunodeficiency, active untreated TB. Severely immunocompromised patients. Pregnancy.
Special Precautions
Patient with history of cerebral injury or seizures, coagulation disorders (e.g. thrombocytopenia), immunosuppression. Postpone vaccination in patients with moderate or severe acute febrile illness. Not indicated for post-exposure prophylaxis against mumps or rubella. Lactation.
Adverse Reactions
Significant: Inj site reactions (e.g. pain, redness, bruising, swelling, induration); syncope, fever, headache.
Gastrointestinal disorders: Nausea, vomiting.
General disorders and administration site conditions: Fatigue, irritability, malaise.
Metabolism and nutrition disorders: Loss of appetite.
Musculoskeletal and connective tissue disorders: Myalgia.
Skin and subcutaneous tissue disorders: Rash.
Potentially Fatal: Hypersensitivity reactions (e.g. anaphylaxis, angioedema).
MonitoringParameters
Monitor for syncope and hypersensitivity reactions 15 minutes after administration.
Drug Interactions
Decreased immune response with immune globulin and immunosuppressive therapies (e.g. high-dose corticosteroids). Reduced therapeutic effect with other live vaccines.
Lab Interference
May interfere with tuberculin test.
Action
Description: Measles, mumps, and rubella (MMR) vaccine is a live attenuated vaccine, that produces active immunity against diseases caused by measles, mumps, and rubella viruses.
Storage
Store between 2-8°C. Protect from light. Do not freeze.
ATC Classification
J07BD52 - measles, combinations with mumps and rubella, live attenuated ; Belongs to the class of morbilli viral vaccines.
Disclaimer: This information is independently developed by MIMS based on Vaccine, MMR from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in